Navigation Links
Jazz Pharmaceuticals, Inc. Announces First Quarter 2009 Financial Results
Date:5/7/2009

- 1Q09 Xyrem(R) net sales of $18 million are 56% higher than 1Q08

- 1Q09 operating expenses of $29 million are 50% lower than 1Q08

PALO ALTO, Calif., May 7 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) today announced financial results for the quarter ended March 31, 2009. Total revenues for the first quarter of 2009 were $22.1 million, compared to $14.6 million for the first quarter of 2008. Xyrem(R) (sodium oxybate) oral solution net sales for the first quarter of 2009 were $17.7 million, an increase of 56% over net sales of $11.3 million for the first quarter of 2008. This increase reflects the effect of significant price increases over the past twelve months and sales volume growth. Net sales of once-daily Luvox CR(R) (fluvoxamine maleate) Extended Release Capsules were $3.6 million for the first quarter of 2009.

Jazz Pharmaceuticals' cash and cash equivalents as of March 31, 2009 were $17.0 million. On March 31, 2009, Jazz Pharmaceuticals did not pay $5.1 million in interest due to the holders of the $119.5 million principal amount of its senior secured notes due June 2011, and Jazz Pharmaceuticals remains in default on the notes. The total overdue interest due on the notes through March 31, 2009 is $9.6 million.

"Our focus for the remainder of 2009 will be on increasing sales of our commercial products for their approved indications and submitting the NDA (New Drug Application) for JZP-6, our sodium oxybate product currently in Phase III clinical trials for the treatment of fibromyalgia," said Bruce Cozadd, Chairman and Chief Executive Officer. "We are pleased to report that we have completed the second pivotal trial for JZP-6 and expect to announce the results in mid-2009. We remain on track to submit our NDA for JZP-6 by the end of the year," he continued. '/>"/>

SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
2. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
3. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
4. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
5. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
6. ACG Announces Major Gift by Salix Pharmaceuticals, Inc.
7. Anthera Pharmaceuticals, Inc. Appoints Donald Santel to Board of Directors
8. Elan Pharmaceuticals, Inc. Licenses Software and Databases From GeneGo
9. Jazz Pharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
10. Acura Pharmaceuticals, Inc. Announces Implementation of Reverse Stock Split and New Trading Symbol: ACPH
11. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2014)... The prevalence of preterm birth the birth of ... is a significant health problem that has increased over ... for Disease Control and Prevention (CDC), preterm birth affects ... eight born in the U.S. While medical care has ... ways to positively impact the neurodevelopmental outcomes of preterm ...
(Date:9/21/2014)... AstraZeneca’s Pulmicort is an ICS ... is used prophylactically for the maintenance treatment of ... budesonide, is an anti-inflammatory corticosteroid with a high ... includes the Pulmicort Flexhaler (budesonide) for adults and ... Pulmicort Respules for children between one and eight ...
(Date:9/21/2014)... 22, 2014 PhUSE is proud to ... Lilliam Rosario as keynote speakers for their 10th annual ... Dr. Ben Goldacre in 2013 , Charles ... in 2011 , PhUSE again presents high-calibre speakers to ... about advancement of clinical information. , Dr. Pritpal Tamber ...
(Date:9/21/2014)... September 21, 2014 The Laboratory Testing ... and manufacturers perform tests on items ranging from consumer ... regulated society, pressure on operators to ensure the safety ... A greater number of government safety regulations and consumer ... prior to sale. Although revenue briefly dipped in 2009 ...
(Date:9/21/2014)... Texas (PRWEB) September 22, 2014 ... the past decade, as it has become saturated ... beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and ... also been facing increasing generic competition. However, the ... once-daily ICS and ICS/LABA therapies delivered by the ...
Breaking Medicine News(10 mins):Health News:Research evaluates neurodevelomental and medical outcomes in single family room NICU 2Health News:Research evaluates neurodevelomental and medical outcomes in single family room NICU 3Health News:Pulmicort Asthma Market (Epidemiology, Etiology, Symptoms, Diagnosis, Pathology) Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 2Health News:Pulmicort Asthma Market (Epidemiology, Etiology, Symptoms, Diagnosis, Pathology) Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 3Health News:Pulmicort Asthma Market (Epidemiology, Etiology, Symptoms, Diagnosis, Pathology) Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 4Health News:PhUSE announces Final List of Industry Influencers as Keynote Speakers 2Health News:PhUSE announces Final List of Industry Influencers as Keynote Speakers 3Health News:Laboratory Testing Services in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Laboratory Testing Services in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Spiriva Asthma Market (Tiotropium Bromide) Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 2Health News:Spiriva Asthma Market (Tiotropium Bromide) Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 3Health News:Spiriva Asthma Market (Tiotropium Bromide) Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 4
... shown to prevent the transmission of HIV as well. Experiments ... or reduce the painful open sores of chancroid on the ... ,Chancroid is a highly contagious STD that is ... United States as well. Antibiotics can be used to effectively ...
... are considered to be a high tech machine and are ... working hard to make it otherwise//. There is a big ... and confusion. Dr J?rg Voskamp, from Germany's Fraunhofer Institute plans ... one’s emotions. A sensitive PC is a research project and ...
... a baby was stillborn last week. But the baby was alive ... before finally succumbing on Saturday. ,Born to Rakesh and ... Rakesh, an auto driver, took him to the burial ground, the ... intensive care unit of the hospital. ,The baby was delivered ...
... A married couple who tried to hoodwink authorities by tying ... collect Rs 5000/- as a reward have been hauled away ... were married 15 years ago and have three children. ... government's mass marriage promotion scheme under which Rs.5,000 is given ...
... 14 which is marked for the celebration of Mother’s day ... India. According to the statistics released by UNICEF// in India ... the world scenario this accounts to more than 20% of ... births there are about 540 maternal deaths. ,There ...
... were investigating eight suspected bird flu cases in humans in ... had been fatal. ,A team from the WHO ... can say they are still suspect at the moment," said ... the Health Ministry's office of communicable disease control, added that ...
Cached Medicine News:Health News:UNICEF Facts & Figures About Maternal Death In India On The Eve Of Mother’s Da 2Health News:UNICEF Facts & Figures About Maternal Death In India On The Eve Of Mother’s Da 3
(Date:9/19/2014)... BALTIMORE and CAMBRIDGE, Mass. ... Diagnostics Inc. (PGDx), a provider of advanced ... Blueprint Medicines , a leader in discovering and ... cancers, today disclosed the first-ever comprehensive genomic study ... and deadly cancer of the female reproductive system, ...
(Date:9/19/2014)... , Sept. 19, 2014  PCI is ... International (Biotec).  Biotec is a leading provider of ... headquartered in Bridgend, Wales ...  The addition significantly expands PCI,s presence in the ... products by adding packaging, storage and distribution capacity, ...
(Date:9/18/2014)... Sept. 18, 2014  Low T Center endorses ... in Hyattsville, Maryland earlier ... the proper patient population for testosterone therapy (TRT), ... associated with TRT. Examining recent claims from studies that ... "available epidemiological studies do not provide convincing evidence ...
Breaking Medicine Technology:First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 2First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 3First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 4PCI Announces Acquisition Of Biotec 2PCI Announces Acquisition Of Biotec 3PCI Announces Acquisition Of Biotec 4PCI Announces Acquisition Of Biotec 5PCI Announces Acquisition Of Biotec 6Low T Center Endorses The Joint FDA Committee Meeting on Testosterone 2
... June 8, 2011 Medco Health Solutions, Inc. (NYSE: ... its groundbreaking SOCRxATES® community pharmacy program to ... SOCRxATES is a care improvement program that enables ... medical conditions and gaps in care, such as medication ...
... 2011 CANTEL MEDICAL CORP. (NYSE: CMN ... $0.29 per diluted share, on a 24% increase in sales to ... This compares with net income of $4,274,000, or $0.25 per diluted ... 30, 2010.  For the nine months ended April 30, 2011, the ...
Cached Medicine Technology:Medco, State of New Mexico and Community Pharmacists Launch SOCRxATES® Program to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 2Medco, State of New Mexico and Community Pharmacists Launch SOCRxATES® Program to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 3Medco, State of New Mexico and Community Pharmacists Launch SOCRxATES® Program to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 4Cantel Medical Reports 18% Increase in Net Income on 24% Increase in Sales 2Cantel Medical Reports 18% Increase in Net Income on 24% Increase in Sales 3Cantel Medical Reports 18% Increase in Net Income on 24% Increase in Sales 4Cantel Medical Reports 18% Increase in Net Income on 24% Increase in Sales 5
... Auto Suture™ PREMIUM SURGICLIP™ clip applier consists of ... cartridge containing 15 or 20 titanium clips. , ... a vessel or other tubular structure. As the ... clip is closed around the vessel or structure. ...
... single use stapler places two titanium staples ... and a knife which divides the tissue ... ,The Auto Suture™ Powered LDS™ single use ... abdominal, gynecological, orthopedic, and thoracic surgery for ...
The ALLPORT and ALLPORT LS Endoscopic Rotating Multiple Clip Appliers have application for use on tubular structures or vessels. The tissue being ligated should be consistent with the size of the cli...
... 20/20 Multiple Clip Applier is a sterile ... This automatic instrument is preloaded with 20 ... by means of the unique Klieman feed ... is reloadable once with a reload containing ...
Medicine Products: